Clinical Trial Update: Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis [Phase 2]

View source ↗

Summary

Phase 2 dose-exploration trial evaluating voclosporin for focal segmental glomerulosclerosis was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis

Drugs mentioned

• Voclosporin (voclosporin)

Snippet

Sponsor: Aurinia Pharmaceuticals Inc. | Conditions: Focal Segmental Glomerulosclerosis | Phase 2 | Status: TERMINATED | Results posted: 2021-09-16